文献速递哮喘

每日一次莫米松联合茚达特罗治疗控制不佳哮喘的3期研究

Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.
PubMed 文献 · Lancet Respir Med · 2020-07-09

PALLADIUM研究为52周随机双盲三模拟3期试验,纳入2216例控制不佳哮喘患者,比较每日一次MF-IND与MF单药及每日两次FLU-SAL。结果显示MF-IND在改善第26周谷FEV1方面优于相应MF剂量,高剂量MF-IND对高剂量FLU-SAL非劣效,不良事件发生率各组相似。

要点

  • 每日一次MF-IND较高剂量MF显著改善第26周谷FEV1,高剂量组差值132 mL。
  • 高剂量MF-IND对每日两次高剂量FLU-SAL的谷FEV1改善非劣效(差值36 mL)。
  • MF-IND为哮喘控制提供新的每日一次干粉复方选择。

核心结论

  • 每日一次ICS/LABA复方MF-IND第26周肺功能改善优于ICS单药MF,高剂量MF-IND对每日两次高剂量FLU-SAL非劣效。

研究设计与样本

  • 52周随机双盲三模拟平行组3期研究,24国316中心,纳入2216例12–75岁控制不佳哮喘患者,按1:1:1:1:1随机分组。

主要发现

  • 高剂量MF-IND较高剂量MF的谷FEV1差值132 mL(95%CI 88–176),p<0·001。
  • 中剂量MF-IND较中剂量MF的谷FEV1差值211 mL(95%CI 167–255),p<0·001。
  • 高剂量MF-IND对高剂量FLU-SAL的谷FEV1差值36 mL(95%CI -7–80),p=0·101。
  • 不良事件发生率各组相似。
  • 1973例(89·0%)完成研究治疗,234例(10·6%)提前终止。

关键数值与推荐

  • 主要终点为第26周谷FEV1较基线变化,全分析集用重复测量混合模型分析。
  • 非劣效界值为-90 mL。

临床怎么用

  • 对中高剂量ICS或低剂量ICS+LABA控制不佳的哮喘患者,可考虑每日一次MF-IND干粉复方改善肺功能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fixed-dose combinations (FDCs) of inhaled corticosteroids (ICS) and long-acting β2-adrenoceptor agonists (LABA) are considered safe and efficacious in asthma management. Most available FDCs require twice-daily dosing to achieve optimum therapeutic effect. The objective of the PALLADIUM study was to assess the efficacy and safety of once-daily FDC of mometasone furoate plus indacaterol acetate (MF-IND) versus mometasone furoate (MF) monotherapy in patients with inadequately controlled asthma. METHODS: This 52-week, double-blind, triple-dummy, parallel-group, phase 3 study recruited patients from 316 centres across 24 countries. Patients aged 12 to 75 years with a documented diagnosis of asthma for at least 1 year, percentage of predicted FEV1 of 50-85%, and an Asthma Control Questionnaire 7 score of at least 1·5 despite treatment with medium-dose or high-dose ICS or low-dose ICS plus LABA were included. A history of asthma exacerbations was not a study requirement. Participants were randomily assigned (1:1:1:1:1) via interactive response technology to receive one of the following treatments for 52 weeks: high-dose MF-IND (320 μg, 150 μg) or medium-dose MF-IND (160 μg, 150 μg) once daily via Breezhaler; high-dose MF (800 μg [400 μg twice daily]) or medium-dose MF (400 μg once daily) via Twisthaler; or high-dose fluticasone propionate-salmeterol xinafoate (FLU-SAL; 500 μg, 50 μg) twice daily via Diskus. Participants received placebo via inhalation through the Breezhaler, Twisthaler, or Diskus devices in the mornings and evenings, as appropriate. The primary endpoint was improvement in trough FEV1 with high-dose and medium-dose MF-IND versus respective MF doses from baseline at 26 weeks, analysed in the full analysis set by means of a mixed model for repeated measures. High-dose MF-IND once daily was compared with high-dose FLU-SAL twice daily for non-inferiority on improving trough FEV1 at week 26 with a margin of -90 mL using mixed model for repeated measures as one of the secondary endpoints. Safety was assessed in all patients who had received at least one dose of study drug. This study is registered with ClinicalTrials.gov, NCT02554786, and is completed. FINDINGS: Between Dec 29, 2015, and May 4, 2018, 2216 patients were randomly assigned (high-dose MF-IND, n=445; medium-dose MF-IND, n=439; high-dose MF, n=442; medium-dose MF, n=444; high-dose FLU-SAL, n=446), of which 1973 (89·0%) completed the study treatment and 234 (10·6%) prematurely discontinued study treatment. High-dose MF-IND (treatment difference [Δ] 132 mL [95% CI 88 to 176]; p<0·001) and medium-dose MF-IND (Δ 211 mL [167 to 255]; p<0·001) showed superiority in improving trough FEV1 over corresponding MF doses from baseline at week 26. High-dose MF-IND was non-inferior to high-dose FLU-SAL in improving trough FEV1 from baseline at week 26 (Δ 36 mL [-7 to 80]; p=0·101). Overall, the incidence of adverse events was similar across the treatment groups. INTERPRETATION: Once-daily FDC of ICS and LABA (MF-IND) significantly improved lung function over ICS monotherapy (MF) at week 26; high-dose MF-IND was non-inferior to twice-daily combination of ICS and LABA (high-dose FLU-SAL) for improvement in trough FEV1. The combination of MF-IND provides a novel once-daily dry powder option for asthma control. FUNDING: Novartis Pharmaceuticals.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. van Zyl-Smit RN, Krüll M, Gessner C, et al. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study. Lancet Respir Med. 2020. PMID: 32653075. doi:10.1016/S2213-2600(20)30178-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。